BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 05, 2006
 |  BioCentury  |  Tools & Techniques

Angiogenesis switch

Blocking angiogenesis is a popular therapeutic strategy, but the intracellular switch that governs whether blood vessels grow or regress was not identified until very recently. In May, researchers at Harvard Medical School published in The EMBO Journal evidence that the intracellular signaling molecules PI3K and PLC gamma compete for the substrate PI45P2 and that the result determines whether blood vessels grow or regress.

Phosphoinositide 3-kinase (PI3K) is known to play a role in angiogenesis and is widely considered to be a hot target in cancer. But the finding that PI3K competes with phospholipase C (PLC) gamma for PI45P2 (phosphatidylinositol-4,5-bisphosphate) and can directly turn on...

Read the full 521 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >